Were the Pelthos Therapeutics (PTHS) insider sales part of routine compensation-related activity?

Yes. The footnote explains the open-market sales were executed pursuant to a pre-set Rule 10b5-1 trading plan and were undertaken to cover estimated tax liabilities associated with the vesting of restricted stock units granted as compensation.

Director at Pelthos Therapeutics (PTHS) sells 590 shares under plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Pelthos Therapeutics Inc. director Richard Malamut reported small open-market sales of company stock. On April 2, 2026, he sold 310 shares of Common Stock at a weighted average price of $20.5126 per share and 280 shares at a weighted average price of $21.3612 per share. A footnote states these sales were made under a pre-arranged Rule 10b5-1 plan adopted on December 16, 2025, to satisfy estimated tax obligations tied to vesting of restricted stock units granted by the company. After the transactions, he held 27,422 shares directly and 1,040 shares indirectly, jointly with his spouse.

Insider Trade Summary 10b5-1

Net Seller: 590 shares ($12,340)

Net Sell 3 txns

Insider Malamut Richard

Role Director

Sold 590 shs ($12K)

Type	Security	Shares	Price	Value
Sale	Common Stock	310	$20.5126	$6K
Sale	Common Stock	280	$21.3612	$6K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 27,702 shares (Direct); Common Stock — 1,040 shares (Indirect, Jointly held with spouse)

Footnotes (1)

This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer. This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Shares sold (first trade): 310 shares Price per share (first trade): $20.5126 per share Shares sold (second trade): 280 shares +4 more

7 metrics

Shares sold (first trade) 310 shares Common Stock sold on April 2, 2026 at $20.5126

Price per share (first trade) $20.5126 per share Weighted average sale price on April 2, 2026

Shares sold (second trade) 280 shares Common Stock sold on April 2, 2026 at $21.3612

Price per share (second trade) $21.3612 per share Weighted average sale price on April 2, 2026

Total shares sold 590 shares Aggregate open-market sales on April 2, 2026

Direct holdings after transactions 27,422 shares Common Stock directly owned after April 2, 2026 trades

Indirect holdings after transactions 1,040 shares Jointly held with spouse after April 2, 2026

Key Terms

Rule 10b5-1 plan, restricted stock units, weighted average price, Common Stock, +1 more

5 terms

Rule 10b5-1 plan regulatory

"sales, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

restricted stock units financial

"tax obligations in connection with the vesting of restricted stock units granted by the Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average price financial

"The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Common Stock financial

"The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

04/06/2026 - 05:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malamut Richard

(Last)

(First)

(Middle)

C/O PELTHOS THERAPEUTICS INC.

4020 STIRRUP CREEK DRIVE, SUITE 110

(Street)

DURHAM

NORTH CAROLINA

27703

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pelthos Therapeutics Inc. [ PTHS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/02/2026		S⁽¹⁾		310	D	$20.5126⁽²⁾	27,702	D
Common Stock	04/02/2026		S⁽¹⁾		280	D	$21.3612⁽³⁾	27,422	D
Common Stock								1,040	I	Jointly held with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.

2. This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Francis Knuettel II, by power of attorney	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Pelthos Therapeutics (PTHS) disclose for Richard Malamut?

Pelthos Therapeutics reported that director Richard Malamut sold 590 shares of Common Stock in two open-market transactions on April 2, 2026, under a pre-arranged Rule 10b5-1 trading plan designed to cover estimated tax obligations from restricted stock unit vesting.

How many Pelthos Therapeutics (PTHS) shares did the director sell and at what prices?

Richard Malamut sold 310 shares of Pelthos Therapeutics Common Stock at a weighted average price of $20.5126 and 280 shares at a weighted average price of $21.3612. Both trades were executed in multiple lots within disclosed intraday price ranges.

Why were the Pelthos Therapeutics (PTHS) shares sold under a Rule 10b5-1 plan?

The filing states the sales were made under a Rule 10b5-1 plan adopted on December 16, 2025, specifically to satisfy estimated tax obligations arising from the vesting of restricted stock units that had been granted by Pelthos Therapeutics.

How many Pelthos Therapeutics (PTHS) shares does the director hold after these transactions?

Following the reported sales, Richard Malamut directly owned 27,422 shares of Pelthos Therapeutics Common Stock and indirectly held 1,040 additional shares that are jointly owned with his spouse, according to the Form 4 disclosure.